Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV
Theravance Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. FDA meeting on VIBATIV(R) (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.